Improving the delivery of circular RNAs for better therapeutic effects
Official title: Synthetic biology approaches for bio-orthogonal labeling of circular RNAs
Funded at Chimerna Therapeutics INC. · NIH-11069802 · Data updated 2026-11-12
This study is working on making a new type of RNA therapy better and more reliable for patients by improving how these special circular RNAs are made and delivered, so they can effectively help treat various conditions.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Chimerna Therapeutics INC. NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $302,605 |
| NIH project number | 1R43GM157885-01 |
| Project ID | NIH-11069802 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be individuals who are seeking innovative treatments for conditions that could benefit from RNA therapies.
✕Less likely to help
Patients with conditions that do not involve RNA-based therapies may not receive any benefit from this research.
What this research studies
This research focuses on enhancing the stability and delivery of circular RNAs, which are promising for RNA-based therapies due to their resistance to degradation. The team at Chimerna Therapeutics is developing methods to produce these circular RNAs efficiently and purify them for use in treatments. They aim to improve the escape of these RNAs from cellular compartments, which is crucial for their effectiveness. By using innovative techniques, they hope to create a more reliable way to deliver RNA therapies to patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective RNA-based therapies for various diseases, including COVID-19.
How similar studies have gone: Previous research has shown promise in improving RNA delivery methods, indicating that this approach could lead to significant advancements.
Where this research is happening
-
Chimerna Therapeutics INC.
New York, United States Active
Researchers
- Principal investigator: Litke, Jacob — Chimerna Therapeutics INC.
- Study coordinator: Litke, Jacob
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.